Frost Radar™:Transformative Influenza Vaccines, 2020

Frost Radar™:Transformative Influenza Vaccines, 2020

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

RELEASE DATE
29-Oct-2020
REGION
Global
Research Code: D9C3-01-00-00-00
SKU: HC03352-GL-TR_24901

$4,950.00

Special Price $4,207.50 save 15 %

In stock
SKU
HC03352-GL-TR_24901

$4,950.00

$4,207.50 save 15 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Influenza causes respiratory diseases and often leads to large epidemics. Every year about 290,000 to 650,000 people die due to influenza worldwide. Anti-viral drugs available to treat influenza have many limitations making vaccination the most effective tool to prevent seasonal and pandemic influenza outbreaks. Influenza vaccination is highly recommended for vulnerable people such as individuals above 60 years of age, comorbid individuals having chronic metabolic diseases, pregnant women, and children.
Currently, available influenza vaccines are either inactivated or live attenuated influenza viruses. The prime challenge with existing influenza vaccine is the antigenic diversity and variability that results in accumulation of mutation in antigenic regions and compromises the efficacy of existing influenza vaccines putting threat to the management of influenza. The World Health Organization reviews the global influenza data every year and determines the strain of influenza most likely to circulate next season. This approach makes the influenza vaccine highly predictive and reduces efficacy. The influenza vaccine efficacy seen so far is in between 10 to 60%.
Various approaches are under development to improve the efficacy of influenza vaccines such as the generation of the replication-deficient viruses, use of adjuvants, application of nanotechnologies, virus-like protein particles, recombinant DNA technology, peptide and nucleic acid-based vaccines. Efforts are being made to generate broad-spectrum influenza vaccines, generally known as universal influenza vaccines, that can provide long-lasting protection against a wide variety of influenza strains across all age groups, and eliminate the need of updating influenza vaccine every season.
Another challenge comes from currently used manufacturing technique based on chicken eggs that have the risk of introduction of mutations in the antigen, potential allergy against egg proteins, slow production process. New technologies such as cell-based and plant-based manufacturing approach can overcome most of the limitations associated with egg-based production.
This Frost Radar™ analyses companies with vaccine candidates and clinical developments for next generation of influenza vaccine.

Table of Contents

Strategic Imperative

Strategic Imperative (continued)

Growth Environment

Growth Environment (continued)

Growth Environment (continued)

Frost Radar™: Transformative Influenza Vaccines

Frost Radar™

Frost Radar™

BiondVax Pharmaceuticals Ltd.

Blue Water Vaccines

DistributedBio

Emergex Vaccines

FluGen Inc.

Imutex

Medicago

Novavax

Osivax

Seqirus

Vaxart

Vivaldi Biosciences

Strategic Insights

Significance of Being on the Frost Radar™

Frost Radar™ Empowers the CEO’s Growth Team

Frost Radar™ Empowers Investors

Frost Radar™ Empowers Customers

Frost Radar™ Empowers the Board of Directors

Frost Radar™: Benchmarking Future Growth Potential

Frost Radar™: Benchmarking Future Growth Potential

Legal Disclaimer

Related Research
Influenza causes respiratory diseases and often leads to large epidemics. Every year about 290,000 to 650,000 people die due to influenza worldwide. Anti-viral drugs available to treat influenza have many limitations making vaccination the most effective tool to prevent seasonal and pandemic influenza outbreaks. Influenza vaccination is highly recommended for vulnerable people such as individuals above 60 years of age, comorbid individuals having chronic metabolic diseases, pregnant women, and children. Currently, available influenza vaccines are either inactivated or live attenuated influenza viruses. The prime challenge with existing influenza vaccine is the antigenic diversity and variability that results in accumulation of mutation in antigenic regions and compromises the efficacy of existing influenza vaccines putting threat to the management of influenza. The World Health Organization reviews the global influenza data every year and determines the strain of influenza most likely to circulate next season. This approach makes the influenza vaccine highly predictive and reduces efficacy. The influenza vaccine efficacy seen so far is in between 10 to 60%. Various approaches are under development to improve the efficacy of influenza vaccines such as the generation of the replication-deficient viruses, use of adjuvants, application of nanotechnologies, virus-like protein particles, recombinant DNA technology, peptide and nucleic acid-based vaccines. Efforts are being made to generate broad-spectrum influenza vaccines, generally known as universal influenza vaccines, that can provide long-lasting protection against a wide variety of influenza strains across all age groups, and eliminate the need of updating influenza vaccine every season. Another challenge comes from currently used manufacturing technique based on chicken eggs that have the risk of introduction of mutations in the antigen, potential allergy against egg proteins, slow production process. New technologies such as cell-based and plant-based manufacturing approach can overcome most of the limitations associated with egg-based production. This Frost Radar™ analyses companies with vaccine candidates and clinical developments for next generation of influenza vaccine.
More Information
No Index No
Podcast No
Author Harshal Patil
Industries Healthcare
WIP Number D9C3-01-00-00-00
Is Prebook No